Eli Lilly to unveil phase III EMBER-3 trial results for Imlunestrant at San Antonio Breast Cancer Symposium
Eli Lilly and Company announced that data from the Phase III trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first… read more.
